Drug intelligence / Profile preview

NASAL-PPGV-FLU

Development stage: Preclinical
Lead developer: PharmaPlanter Technologies
Modality: Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

NASAL-PPGV-FLU is a preclinical-stage mucosal vaccine candidate developed by PharmaPlanter Technologies. It utilizes a Gas Vesicle Nanoparticle (GVNP) platform to deliver antigens from SARS-CoV-2 (COVID-19), Influenza A, and Influenza B. Administered intranasally, the vaccine is designed to induce both local mucosal immunity at the site of entry and systemic immune responses. The GVNP technology serves as a self-adjuvanting delivery vehicle that presents viral antigens to the immune system, potentially offering broad protection against respiratory viral infections.

Other names: PPGV-FLUGas Vesicle Nanoparticle mucosal vaccine

Targets

Flu (Influenza surface proteins)

Beyond the preview

Go deeper on NASAL-PPGV-FLU.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NASAL-PPGV-FLU.

Explore the full profile